Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

A Phase 2 Multicenter Study of Pegaspargase in Combination with Gemcitabine, Etoposide, Mitoxantrone Hydrochloride Liposome, and Dexamethasone (P-GEMD) for Newly Diagnosed Early Non-Upper Aero-Digestive Tract or Advanced Stage Extranodal NK/T Cell Lymphoma

Jinhua Liang, Hao-Rui Shen, Hua Yin, Jiazhu Wu, Yue Li, Li Wang, Jianyong Li, Liang Wang, Xu Wei

Blood (2024) 144 (Supplement 1): 6396.

https://doi.org/10.1182/blood-2024-203071

Published: 2024

Journal Articles

Polatuzumab Vedotin-Based Regimens As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Xin-di Liu, Jia Cong, Jing Yang, Liang Wang

Blood (2024) 144 (Supplement 1): 6545.

https://doi.org/10.1182/blood-2024-203066

Published: 2024

Journal Articles

Orelabrutinib with or without Anti-CD20 Monoclonal Antibodies Is Highly Effective and Well Tolerated As First-Line Therapy for Marginal Zone B Cell Lymphoma

Na Yao, Xin Li, Jing Yang, Jia Cong, Liang Wang

Blood (2024) 144 (Supplement 1): 6541.

https://doi.org/10.1182/blood-2024-203548

Published: 2024

Journal Articles

Rapid Step-up Dosing Schedule of Glofitamab Is Feasible for Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Jing Yang, Liang Wang

Blood (2024) 144 (Supplement 1): 6540.

https://doi.org/10.1182/blood-2024-202904

Published: 2024

Journal Articles

Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)

Xin Li, Jia Wei, Dong-feng Zeng, Shu-nan Qi, Bingzong Li, Wei Guo, Li Wang, Yajun Li, Xudong Zhang, Yong Yang, Shukai Qiao, Yan Zeng, Yunfei Song, Jing-wen Wang, Jian-min Ma, Liang Wang

Blood (2024) 144 (Supplement 1): 4418.

https://doi.org/10.1182/blood-2024-206489

Published: 2024

Journal Articles

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

Blood (2024) 144 (Supplement 1): 4450.

https://doi.org/10.1182/blood-2024-209224

Published: 2024

Journal Articles

A Phase Ib/II Clinical Trial of Linperlisib Combined with Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-Cell Lymphoma: Analysis of the Phase Ib Part

Lei Yang, Xin Li, Jia Cong, Liang Wang

Blood (2024) 144 (Supplement 1): 6413.

https://doi.org/10.1182/blood-2024-207469

Published: 2024

Journal Articles

Single-Cell RNA Sequencing of CAR-T Cell Infusion Products Reveals ‘viral Mimicry’ As Potential Resistance Mechanism

Xiaojie Liang, Weixiang Lu, Liang Wang

Blood (2024) 144 (Supplement 1): 7170.

https://doi.org/10.1182/blood-2024-198300

Published: 2024

Journal Articles

Outcomes and Clinical Practice Among Patient with Chronic Lymphocytic Leukemia Treated with Ibrutinib in China: A Real-World Experience

Shenmiao Yang, Ru Feng, Xutao Guo, Zhenling Li, Qianqian Ju, Yujun Dong, Bingjie Wang, Yu Zhao, Liang Wang, Wanling Sun, Fang Fang, Liru Wang, Liping Su, Xiaojun Huang

Blood (2024) 144 (Supplement 1): 7819.

https://doi.org/10.1182/blood-2024-210572

Published: 2024

Journal Articles

Mitoxantrone Hydrochloride Liposome Combined with Polatuzumab Vedotin and Dexamethasone (MPD) Is Highly Effective and Well Tolerated As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Xin-di Liu, Jia Cong, Lei Yang, Jing Yang, Liang Wang

Blood (2024) 144 (Supplement 1): 6475.

https://doi.org/10.1182/blood-2024-209754

Published: 2024

Journal Articles

BR105 Is a Novel Anti-Sirpα Monoclonal Antibody That Demonstrates a Favorable Safety Profile and Potent Anti-Tumor Efficacy in Patients with Relapsed/Refractory Lymphoid Malignancies: Preliminary Results from a Phase I Study

Ningjing Lin, Tingting Du, Hui Zhou, Yajun Li, Liang Wang, Xiaomeng Dong, Haochuan Zheng, Jingtao Lu, Mi Tang, Jihua Wu, Wei Zhu, Yuqin Song, Jun Zhu

Blood (2024) 144 (Supplement 1): 4175.

https://doi.org/10.1182/blood-2024-206674

Published: 2024

Journal Articles

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Shenmiao Yang, Huayuan Zhu, Ru Feng, Xutao Guo, Ting Niu, Jian-Qing Mi, Zhenling Li, Qianqian Ju, Liru Wang, Yujun Dong, Bingjie Wang, Liang Wang, Wanling Sun, Fang Fang, Liping Su, Yu Zhao, Xiaojun Huang, Jianyong Li

Blood (2024) 144 (Supplement 1): 6773.

https://doi.org/10.1182/blood-2024-206560

Published: 2024

Journal Articles

ΔSUV max between Baseline and Interim 18 f-FDG PET/CT Scans Could Better Assess the Early Response to Induction Therapy and Identify False-Positive Findings at Interim PET/CT in Extranodal NK/T-Cell Lymphoma

Lijie Zeng, Lei Yang, Mei Li, Liang Wang

Blood (2024) 144 (Supplement 1): 3073.

https://doi.org/10.1182/blood-2024-210595

Published: 2024

Journal Articles

A Novel Nomogram Predicting Rituximab-Associated Interstitial Pneumonia in Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of Single-Center

Jia Guo, Chengji Wang, Yuanzheng Liang, Liang Wang

Blood (2023) 142 (Supplement 1): 6259.

https://doi.org/10.1182/blood-2023-180826

Published: 2023

Journal Articles

A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma

Huangming Hong, Mingzhi Zhang, Zhigang Peng, Jianzhen Shen, Yuerong Shuang, Hui Zhou, Hongqiang Guo, He Huang, Fei Li, Zhengzi Qian, Lihong Liu, Liang Wang, Wei Yang, Liling Zhang, Pengcheng He, Shen Qian, Fugen Li, Meng Li, Tongyu Lin

Blood (2023) 142 (Supplement 1): 304.

https://doi.org/10.1182/blood-2023-180372

Published: 2023

Journal Articles

Efficacy and Safety Analysis of Combination Therapy Based on Liposomal Mitoxantrone (Lipo-MIT) in Relapsed/Refractory NK/T-Cell Lymphoma

Liang Wang, Jing Yang, Liqiang Wei

Blood (2023) 142 (Supplement 1): 6210.

https://doi.org/10.1182/blood-2023-182678

Published: 2023

Journal Articles

Efficacy and Safety of BTK Inhibitors in Vitreoretinal Lymphoma: A Single-Center, Retrospective Analysis of 24 Patients

Jing Gao, Liang Wang

Blood (2023) 142 (Supplement 1): 3134.

https://doi.org/10.1182/blood-2023-180354

Published: 2023

Journal Articles

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Clinical Trial

Qingqing Cai, Yi Xia, Liang Wang, Huiqiang Huang, Jinni Wang, Jun Cai, Xiaopeng Tian

Blood (2023) 142 (Supplement 1): 4470.

https://doi.org/10.1182/blood-2023-188430

Published: 2023

Journal Articles

Untargeted Metabolomics of Cerebrospinal Fluid in Patients with Primary Central Nervous System Lymphoma

Xiaoyue Wang, Ji Ma, Liang Wang

Blood (2022) 140 (Supplement 1): 11921–11922.

https://doi.org/10.1182/blood-2022-162899

Published: 2022

Journal Articles

A Multicenter, Single-Arm, Prospective Phase II Study of Orelabrutinib Combined with High-Dose Methotrexate and Rituximab Sequential Autologous Hematopoietic Stem Cell Transplantation in Newly-Dignosed Primary Central Nervous System Lymphoma

Ji Ma, Qiang He, Ke Lu, Liang Wang

Blood (2022) 140 (Supplement 1): 3744–3745.

https://doi.org/10.1182/blood-2022-165720

Published: 2022

NARROW

A Phase 2 Multicenter Study of Pegaspargase in Combination with Gemcitabine, Etoposide, Mitoxantrone Hydrochloride Liposome, and Dexamethasone (P-GEMD) for Newly Diagnosed Early Non-Upper Aero-Digestive Tract or Advanced Stage Extranodal NK/T Cell Lymphoma

Polatuzumab Vedotin-Based Regimens As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Orelabrutinib with or without Anti-CD20 Monoclonal Antibodies Is Highly Effective and Well Tolerated As First-Line Therapy for Marginal Zone B Cell Lymphoma

Rapid Step-up Dosing Schedule of Glofitamab Is Feasible for Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

A Phase Ib/II Clinical Trial of Linperlisib Combined with Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-Cell Lymphoma: Analysis of the Phase Ib Part

Single-Cell RNA Sequencing of CAR-T Cell Infusion Products Reveals ‘viral Mimicry’ As Potential Resistance Mechanism

Outcomes and Clinical Practice Among Patient with Chronic Lymphocytic Leukemia Treated with Ibrutinib in China: A Real-World Experience

Mitoxantrone Hydrochloride Liposome Combined with Polatuzumab Vedotin and Dexamethasone (MPD) Is Highly Effective and Well Tolerated As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma

BR105 Is a Novel Anti-Sirpα Monoclonal Antibody That Demonstrates a Favorable Safety Profile and Potent Anti-Tumor Efficacy in Patients with Relapsed/Refractory Lymphoid Malignancies: Preliminary Results from a Phase I Study

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

ΔSUV max between Baseline and Interim 18 f-FDG PET/CT Scans Could Better Assess the Early Response to Induction Therapy and Identify False-Positive Findings at Interim PET/CT in Extranodal NK/T-Cell Lymphoma

A Novel Nomogram Predicting Rituximab-Associated Interstitial Pneumonia in Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of Single-Center

A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma

Efficacy and Safety Analysis of Combination Therapy Based on Liposomal Mitoxantrone (Lipo-MIT) in Relapsed/Refractory NK/T-Cell Lymphoma

Efficacy and Safety of BTK Inhibitors in Vitreoretinal Lymphoma: A Single-Center, Retrospective Analysis of 24 Patients

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Clinical Trial

Untargeted Metabolomics of Cerebrospinal Fluid in Patients with Primary Central Nervous System Lymphoma

A Multicenter, Single-Arm, Prospective Phase II Study of Orelabrutinib Combined with High-Dose Methotrexate and Rituximab Sequential Autologous Hematopoietic Stem Cell Transplantation in Newly-Dignosed Primary Central Nervous System Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only